Clara Chan, MD, FRSCS, FACS, DABO, from the University of Toronto spoke with Ophthalmology Times about their study on the consistency of outcomes across 3 different cohorts of patients that were internationally collected at this year's American Academy of Ophthalmology meeting.
Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.
Swarup Swaminathan, MD, spoke with Ophthalmology Times about using the Heidelberg SPECTRALIS and caring for our Glaucoma patients at this year's American Academy of Ophthalmology meeting.
Daniel Chang, MD, spoke with Ophthalmology Times about his poster "Clinical performance of a diffractive, extended depth-of-focus IOL, with violet light filtering and high-resolution lathing" at this year's American Academy of Ophthalmology meeting.
Megan Baldwin, MD, founder of Opthea Limited, spoke with Ophthalmology Times about the company's ShORe and COAST clinical trials at this year's American Academy of Ophthalmology meeting.
Rich Small, CEO of Neurotech, spoke with Ophthalmology Times about the company's development of encapsulated cell therapy, NT-501, at this year's American Academy of Ophthalmology meeting.
Caroline Baumal, Chief Medical Officer at Apellis, spoke with Ophthalmology Times on the GALE extension study of pegcetacoplan for geographic atrophy, and shared insights on her career transition, emphasizing the significance of mentorship and a passion for one’s work at this year's American Academy of Ophthalmology meeting in San Francisco.
Ben Bergo, CEO of Visus Therapeutics spoke with Ophthalmology Times about the study on presbyopia, BRIO-I at this year's American Academy of Ophthalmology meeting.
Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America spoke with Ophthalmology Times about 3 new technologies the company launched at this year's American Academy of Ophthalmology meeting.
Peter K. Kaiser, MD, shares a promising outlook for patients with dry age-related macular degeneration, with innovative therapies in development that have the potential not only to prevent vision loss but also improve visual acuity.
Ophthalmology experiences lower burnout rates compared with other medical fields, but the profession is not immune to the issue, explains Peter J. McDonnell, MD.
Daniel H. Chang, MD, shared highlights of his presentation on a first-in-human clinical feasibility study of a dual-optic accommodating IOL system.
At this year's American Academy of Ophthalmology meeting, Mary Elizabeth Hartnett, MD, of the Byers Eye Institute at Stanford University presented on gender disparities in vision loss and blindness.
Edward J. Holland, MD, and Professor Shigeru Kinoshita, MD, discuss how a single donor cornea could potentially help over a thousand patients.
David Hutton of Ophthalmology Times spent time with Esen K Akpek, MD, who discussed her presentation at this year's American Academy of Ophthalmology meeting.
Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.
Thomas V. Johnson, MD, PhD, notes the value of home monitoring lies in its ability to provide real-time insights into IOP fluctuations, enabling more precise glaucoma care and a deeper understanding of the patient's risk for vision loss.
Orasis Pharmaceuticals CEO Elad Kedar and COO Paul Smith sat down with David Hutton to discuss the FDA approval of Qlosi, a preservative-free low-dose eyedrops for presbyopia.
Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."
Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."
Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."
Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."
Experts in the field weigh in on and give opinions on the question "What do you wish patients knew about eye health."
Lisa M. Nijm, MD, JD, discusses the action-packed agenda of Real World Ophthalmology’s virtual event on September 30, 2023.
Debbie Allen, an award-winning actress, dancer, choreographer, singer-songwriter, director and producer is teaming up with Prevent Blindness and Regeneron for the Gr8 Eye Movement, an awareness campaign that aims to educate and encourage those who are at risk of certain retinal diseases to prioritize their eye health.
At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!
Our team spoke with several researchers and industry professionals at the 2023 American Society of Retina Specialists meeting in Seattle, Washington. We asked them, "What research here do you find exciting or interesting?" Here's what Tarek Hassan, MD, Nancy Lurker, and J. Fernando Arevalo, MD, PhD, FACS, FASRS, had to say.
At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say.
Eva Kim, MD, spoke with our team to share insights from her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.
Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.
